Crowdonomics
WatchlistPortfolio
All companies
MICOY THERAPEUTICS logo

MICOY THERAPEUTICS

Operating

Micoy Therapeutics, Inc.

Biotech · Biotech · Founded 2024

Visit website

Developing therapeutics to block harmful autoantibodies

Post-money valuation ⓘ
$10.1M
As of Apr 2025 · from Reg CF Offering (2024) · pre-money + amount raised, not a traded price
Total raised
$100,200
Crowd $0 · Private $100K · 2 rounds since 2024
Latest share price
$0.0501
Section 4(a)(2) · Common Stock · Jul 2024 offering price

Financials

FY2022–FY2023 · from SEC filings · hover any figure for its source
$0
−$136K
2022
$0
−$1.5M
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022 reviewed
FY2023 reviewed
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$136,210
-$1,451,848
Taxes paid
$0
$0
Balance sheet
Cash
$0
$0
Accounts receivable
$0
$0
Total assets
$0
$0
Short-term debt
$0
$0
Long-term debt
$0
$0
Total liabilities
$0
$0
Other
Headcount
—
4

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$10.0M
pre-money
Reg CF · Common · Oct 2024

Blue bars are the pre-money valuation the company stated for a priced round.

Fundraising history

Reg CF · Common Stock · Oct 2024Closedvia StartEngine
Raised $0 / $1.2MPost-money $10.1M

Team

2 people
Prem Premsrirut
CEO, Director
David Eads
CFO, Secretary, Treasurer

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Delinquent

Filed 0 of 2 annual reports (FY2024–FY2025)

Missing: 2024, 2025

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-UApr 16, 20250001665160-25-000688
    EDGAR
  • Form C/AJan 23, 20250001665160-25-000117
    EDGAR
  • Form C-UDec 5, 20240001665160-24-001766
    EDGAR
  • Form COct 29, 20240001665160-24-001489
    EDGAR
Source: ManualCIK 0002041723Share price $1.75

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.